Traws Pharma Dips as Company Expands Outbreak Drug Play
Traws Pharma shares fell about 5% early Friday to $1.40 amid a broader biotech slide after U.S. jobs data. The company reported a Q1 net loss of $7.1 million with $3.1 million in cash and no revenue, and is pursuing a $60 million PIPE deal. Traws is advancing a preclinical antiviral for Ebola, Lassa, and hantavirus, but has no human or animal efficacy data. An at-the-market program could add up to $3.13 million in new shares.